Nearly four in 10 Americans believe cancer can be cured solely through alternative therapies, according to the American Society of Clinical Oncology's second annual National Cancer Opinion Survey.
Research in the October 2018 issue of JNCCN—Journal of the National Comprehensive Cancer Network--identifies risk factors for chemotherapy-induced febrile neutropenia.
Merck announced the first presentation of interim data from the pivotal phase III KEYNOTE-048 trial investigating Keytruda as both monotherapy and in combination with chemotherapy for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Merck announced the first presentation of results from an interim analysis of KEYNOTE-057, a phase II trial evaluating Keytruda (pembrolizumab) for previously treated patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ or CIS plus papillary disease (Cohort A).
Loxo Oncology Inc. and Bayer AG announced updated clinical data for larotrectinib, an investigational oral, selective, and CNS-active TRK inhibitor, in adult and pediatric patients with TRK fusion cancers.
Pfizer Inc. announced detailed overall survival data from the PALOMA-3 trial, which evaluated Ibrance (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer whose disease progressed on or after prior endocrine therapy.
Soligenix Inc. said it has received a positive recommendation from the independent Data Monitoring Committee to continue enrolling into the company's phase III “Fluorescent Light Activated Synthetic Hypericin” study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma.
Merck announced the first presentation of preliminary data from a phase I clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.
Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive early breast cancer, according to results reported at ESMO 2018 Congress in Munich.
AstraZeneca and Merck & Co., Inc. announced detailed results from the phase III SOLO-1 trial testing Lynparza (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.
